Valneva Expects Further Sales Growth

Dow Jones

Feb 18, 2025

By Helena Smolak

Valneva expects further sales growth this year after it posted higher revenue in 2024.

The French vaccine company said Tuesday that it expects total revenue in 2025 to grow to between 180 million euros and 190 million euros ($188.7 million and $199.2 million) with a positive cashflow. It expects to reach R&D investments of between 90 million and 100 million euros for this year.

Its full-year revenue rose 10% to 169.6 million euros despite lower-than anticipated sales of its attenuated chikungunya vaccine in the U.S.

Its cash and cash equivalents stood at 168.3 million euros as of Dec. 31.

The company will publish its audited full-year results on Mar. 20.

Write to Helena Smolak at helena.smolak@wsj.com

(END) Dow Jones Newswires

February 18, 2025 03:13 ET (08:13 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2512358521"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512358521\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512358521?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-18 16:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512358521","market":"hk","top_or_hot":-1,"title":"Valneva Expects Further Sales Growth","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Helena Smolak \n</p>\n<pre>\n \n</pre>\n<p>\n   Valneva expects further sales growth this year after it posted higher revenue in 2024. \n</p>\n<p>\n  The French vaccine company said Tuesday that it expects total revenue in 2025 to grow to between 180 million euros and 190 million euros ($188.7 million and $199.2 million) with a positive cashflow. It expects to reach R&amp;D investments of between 90 million and 100 million euros for this year. \n</p>\n<p>\n  Its full-year revenue rose 10% to 169.6 million euros despite lower-than anticipated sales of its attenuated chikungunya vaccine in the U.S. \n</p>\n<p>\n  Its cash and cash equivalents stood at 168.3 million euros as of Dec. 31. \n</p>\n<p>\n  The company will publish its audited full-year results on Mar. 20. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Helena Smolak at helena.smolak@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2025 03:13 ET (08:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva Expects Further Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva Expects Further Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-18 16:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Helena Smolak \n</p>\n<pre>\n \n</pre>\n<p>\n   Valneva expects further sales growth this year after it posted higher revenue in 2024. \n</p>\n<p>\n  The French vaccine company said Tuesday that it expects total revenue in 2025 to grow to between 180 million euros and 190 million euros ($188.7 million and $199.2 million) with a positive cashflow. It expects to reach R&amp;D investments of between 90 million and 100 million euros for this year. \n</p>\n<p>\n  Its full-year revenue rose 10% to 169.6 million euros despite lower-than anticipated sales of its attenuated chikungunya vaccine in the U.S. \n</p>\n<p>\n  Its cash and cash equivalents stood at 168.3 million euros as of Dec. 31. \n</p>\n<p>\n  The company will publish its audited full-year results on Mar. 20. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Helena Smolak at helena.smolak@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2025 03:13 ET (08:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VALN","symbol_name":"Valneva SE","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2512358521","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512358521","pubTimestamp":1739866380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Valneva expects further sales growth this year after it posted higher revenue in 2024.The French vaccine company said Tuesday that it expects total revenue in 2025 to grow to between 180 million euros and 190 million euros  with a positive cashflow. It expects to reach R&D investments of between 90 million and 100 million euros for this year.Its full-year revenue rose 10% to 169.6 million euros despite lower-than anticipated sales of its attenuated chikungunya vaccine in the U.S.Its cash and cash equivalents stood at 168.3 million euros as of Dec. 31.The company will publish its audited full-year results on Mar. 20.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"VALN":"Valneva SE"},"translate_title":"Valneva预计销售额将进一步增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VALN":0.9},"content_text":"By Helena Smolak \n\n\n \n\n\n   Valneva expects further sales growth this year after it posted higher revenue in 2024. \n\n\n  The French vaccine company said Tuesday that it expects total revenue in 2025 to grow to between 180 million euros and 190 million euros ($188.7 million and $199.2 million) with a positive cashflow. It expects to reach R&D investments of between 90 million and 100 million euros for this year. \n\n\n  Its full-year revenue rose 10% to 169.6 million euros despite lower-than anticipated sales of its attenuated chikungunya vaccine in the U.S. \n\n\n  Its cash and cash equivalents stood at 168.3 million euros as of Dec. 31. \n\n\n  The company will publish its audited full-year results on Mar. 20. \n\n\n \n\n\n  Write to Helena Smolak at helena.smolak@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 03:13 ET (08:13 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}